OptimizeRx Corp (OPRX): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
OptimizeRx Corp (OPRX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001448431 0001448431 2026-06-01 2026-06-01 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor
How this was made
The 30-second read
Why it matters
The key new information is the specific compensation package (salary continuation, bonus target lump sum, COBRA reimbursement) and the 12-month advisory role through June 15, 2027, including non-compete and non-solicit obligations.
Market read
This is a leadership transition disclosure that may affect perceived commercial execution risk, but it lacks financial or operational performance updates.
What to watch
Investors may focus on whether a replacement CCO is named and how responsibilities are reassigned; the filing does not specify interim commercial leadership.
Background
OptimizeRx previously disclosed the separation arrangement in its 10-Q for the quarter ended March 31, 2026; this 8-K provides the separation and advisory agreement details.
Ticker impact
OptimizeRx disclosed the separation of Chief Commercial Officer Theresa Greco effective June 15, 2026, including advisory services and compensation terms.
Likely limited immediate price impact unless investors interpret the CCO exit as a commercial execution risk; watch for follow-on disclosures on commercial leadership and strategy.
The filing is a primary SEC 8-K event (Item 5.02) with concrete terms, but it does not include guidance, financial results, or a new product/contract catalyst.
Market effects
No direct sector read-across; this is company-specific leadership/compensation disclosure.
None indicated; US-listed Nasdaq Capital Market issuer filing.
None indicated.
Counterpoint
The advisory term and continued vesting suggest the company is managing continuity rather than signaling a breakdown in commercial execution.
Key entities
- executiveTheresa Greco
Former Chief Commercial Officer; separation effective June 15, 2026 with 12-month advisory services and defined compensation.
